Targeting the opioid growth factor: Opioid growth factor receptor axis for treatment of human ovarian cancer

Experimental Biology and Medicine

Volumn 238, Issue 5, 2013, Pages 579-587

  Zagon, Ian S ^a   Donahue, Renee ^a   Mclaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Met5 enkephalin; Cell proliferation; DNA synthesis; Naltrexone; OGF; OGFr; Ovarian cancer

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; METENKEPHALIN; NALTREXONE; OPIOID GROWTH FACTOR; OPIOID GROWTH FACTOR RECEPTOR; PACLITAXEL; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; DNA MODIFICATION; DNA SYNTHESIS; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; LOW DRUG DOSE; NONHUMAN; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME;

[MET5]-ENKEPHALIN; CELL PROLIFERATION; DNA SYNTHESIS; NALTREXONE; OGF; OGFR; OVARIAN CANCER;

APOPTOSIS; CELL CYCLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; NECROSIS; NEOPLASM PROTEINS; OPIOID PEPTIDES; OVARIAN NEOPLASMS; RECEPTORS, OPIOID; UP-REGULATION;

EID: 84881605592     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213488483     Document Type: Article

References (84)

1. Romero I, Bast RC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 2012;153:1593-602.
2. Leung PCK, Choi J-H. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 2007;13:143-62.
3. Bast RC. CA125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer 2010;116:2850-3.
4. Soslow RA. Histologic subtypes of ovarian carcinomas: an overview. Int J Gynecol Pathol 2008;27:161-74.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
6. Howlander N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhi J, Tatlovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA. (eds). SEER Cancer Statistics Review, 1975-2009, National Cancer Institute, Bethesda, MD. See http://seer.cancer.gov/statfacts.html.ovary.html.
7. American Cancer Society. Cancer Facts and Figures 2012. Altanta GA: American Cancer Society, 2012.
8. Lynch HT, Watson P, Lynch J, Conway TA, Fili M. Hereditary ovarian cancer. Heterogeneity in age at onset. Cancer 1993;71(Suppl 2): 573-81.
9. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993;71(Suppl 2): 517-23.
10. Penson RT, Shannon KE, Sharpless NE, Seiden MV. Ovarian cancer: an update on genetics and therapy. Compr Ther 1998;24:477-87.
11. Piver MS, Goldberg JM, Tsukada Y, Mettlin CJ, Jishi MF, Natarajan N. Characteristics of familial ovarian cancer: a report of the first 1000 families in the Gilda Radner Familial Ovarian Cancer Registry. Eur J Gynaecol Oncol 1996;17:169-76.
12. Wooster R, Newhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265:2088-90.
13. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
14. See https://www.caring4cancer.com/go/ovarian/treatments
15. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science 1983;221:671-3.
16. Zagon IS, McLaughlin PJ. Increased brain size and cellular content in infant rats treated with an opiate antagonist. Science 1983;221:1179-80.
17. Zagon IS, McLaughlin PJ. Endogenous opioid systems regulate cell proliferation in the developing rat brain. Brain Res 1987;412:68-72.
18. McLaughlin PJ, Zagon IS. Modulation of human neuroblastoma transplanted into nude mice by endogenous opioid systems. Life Sci 1987;41:1465-72.
19. Zagon IS, Rhodes RE, McLaughlin PJ. Distribution of enkephalin immunoreactivity in germinative cells of developing rat cerebellum. Science 1985;227:1049-51.
20. Zagon IS, Rhodes RE, McLaughlin PJ. Localization of enkephalin immunoreactivity in diverse tissues and cells of the developing and adult rat. Cell Tiss Res 1986;246:561-5.
21. Meilandt WJ, Yu Gui-Qiu, Roberson ED, Palop JJ, Wu T, Scearce- Levie K, Mucke L. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2008;28:5007-17.
22. 5]-enkephalin. Amer J Physiol 1996;271:R122-9.
23. Zagon IS, Wu Y, McLaughlin PJ. The opioid growth factor, [Met5]- enkephalin, and the z (zeta) opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis. J Invest Dermatol 1996;106:490-7.
24. Zagon IS, Sassani JW, Kane ER, McLaughlin PJ. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor. Brain Res 1997;759:92-102.
25. Zagon IS, Hytrek SD, McLaughlin PJ. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Amer J Physiol 1996;271:R511-8.
26. Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 1999;14:577-84.
27. McLaughlin PJ, Zagon IS, Skitzki J. Human neuroblastoma cell growth in tissue culture is regulated by opioid growth factor. Int J Oncol 1999;14:373-80.
28. McLaughlin PJ, Levin RJ, Zagon IS. Regulation of human head and neck squamous cell carcinoma growth in tissue culture by the opioid growth factor. Int J Oncol 1999;14:991-8.
29. Bisignani GJ, McLaughlin PJ, Ordille SD, Jarowenko MJ, Zagon IS. Human renal cell proliferation in tissue culture is tonically inhibited by opioid growth factor. J Urol 1999;162:2186-91.
30. McLaughlin PJ, Goldenberg D, Park SS, Conway A, Donahue RN, Zagon IS. Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) -opioid growth factor receptor (OGFr) axis. BMC Cancer 2009;9:369.
31. Avella DM, Kimchi ET, Donahue RN, Tagaram HR, McLaughlin PJ, Zagon IS, Staveley-O'Carroll KF. The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Amer J Physiol Regul Integr Comp Physiol 2010;298:R459-66.
32. Zagon IS, Porterfield NK, McLaughlin PJ. Opioid growth factor (OGF) -opioid growth factor receptor (OGFr) axis inhibits proliferation of triple negative breast cancer. Exp Biol Med 2013, in press
33. Zagon IS, Donahue RN, McLaughlin PJ. Opioid growth factoropioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Amer J Physiol 2009;297:R1154-R1161.
34. Zagon IS, McLaughlin PJ. An opioid growth factor regulates the replication of microorganisms. Life Sci 1992;50:1179-87.
35. Zagon IS, McLaughlin PJ. Identification of opioid peptides regulating proliferation of neurons and glia in the developing nervous system. Brain Res 1991;542:318-23.
36. 5]-enkephalin in developing, adult, and renewing tissues by reversed-phase highperformance liquid chromatography and radioimmunoassay. Life Sci 1997;61:363-70.
37. Mosnaim AD, Puente J, Wolf ME, Callaghan OH, Busch R, Diamond S. Studies of the in vitro human plasma degradation of methionineenkephalin. Gen Pharmacol 1988;19:729-3.
38. Zagon IS, McLaughlin PJ. Naltrexone modulates body and brain development in rats: a role for endogenous opioids in growth. Life Sci 1984;35:2057-64.
39. Zagon IS, McLaughlin PJ. Duration of opiate receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer. Life Sci 1984;35:409-16.
40. Zagon IS, McLaughlin PJ. Opiate-antagonist induced regulation of organ development. Physiol Behav 1985;34:507-11.
41. Zagon IS, McLaughlin PJ. Opioid antagonist (naltrexone) modulation of cerebellar development: histological and morphometric studies. J Neurosci 1986;6:1424-32.
42. Zagon IS, McLaughlin PJ. Modulation of murine neuroblastoma in nude mice by opioid antagonists. J Natl Cancer Inst 1987;78:141-7.
43. Zagon IS, McLaughlin PJ. Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res 1989;480:16-28.
44. Zagon IS, McLaughlin PJ. Naloxone modulates body and organ growth of rats: dependency on the duration of opioid receptor blockade and stereospecificity. Pharmacol Biochem Behav 1989;33:325-8.
45. Zagon IS, McLaughlin PJ. Opioid antagonist (naltrexone) stimulation of cell proliferation in human and animal neuroblastoma and human fibrosarcoma cells in culture. Neuroscience 1990;37:223-6.
46. Zagon IS, Goodman SR, McLaughlin PJ. Characterization of opioid binding sites in murine neuroblastoma. Brain Res 1988;449:80-8.
47. Zagon IS, Goodman SR, McLaughlin PJ. Characterization of zeta (z): a new opioid receptor involved in growth. Brain Res 1989;482:297-305.
48. Zagon IS, Goodman SR, McLaughlin PJ. Demonstration and characterization of zeta (z), a growth-related opioid receptor, in a neuroblastoma cell line. Brain Res 1990;511:181-8.
49. Zagon IS, Gibo DM, McLaughlin PJ. Zeta (z), a growth-related opioid receptor in the developing rat cerebellum: identification and characterization. Brain Res 1991;551:28-35.
50. Zagon IS, Goodman SR, McLaughlin PJ. Zeta (z), the opioid growth factor receptor: identification and characterization of binding subunits. Brain Res 1993;605:50-6.
51. Zagon IS, Verderame MF, Allen S, McLaughlin PJ. Cloning, sequencing, expression, and function of a cDNA encoding a receptor for the opioid growth factor, [Met5]-enkephalin. Brain Res 1999;849:147-54.
52. Zagon IS, Verderame MF, Allen SS, McLaughlin PJ. Cloning, sequencing, chromosomal location, and function of cDNAs encoding an opioid growth factor receptor (OGFr) in humans. Brain Res 2000;856:75-83.
53. Zagon IS, Verderame MF, Zimmer WE, McLaughlin PJ. Molecular characterization and distribution of the opioid growth factor receptor (OGFr) in mouse. Mol Brain Res 2000;84:106-14.
54. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Rev 2002;38:351-76.
55. Zagon IS, Ruth TB, Leure-duPree AE, Sassani JW, McLaughlin PJ. Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res 2003;967:37-7.
56. Zagon IS, Ruth TB, McLaughlin PJ. Nucleocytoplasmic distribution of opioid growth factor (OGF) and its receptor (OGFr) in tongue epithelium. Anat Rec A: Discov Mol Cell Evol Biol 2005;282:24-37.
57. Cheng F, McLaughlin PJ, M F. Verderame, Zagon IS. Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp Biol Med 2009;234:532-41.
58. Tanner MM, Grenman S, Koul A, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000;6:1833-9.
59. Donahue RN, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol 2009;296:R1716-25.
60. McLaughlin PJ, Levin RJ, Zagon IS. Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. Cancer Lett 2003;199:209-17.
61. McLaughlin PJ, Stack BC, Braine KM, Ruda JD, Zagon IS. Opioid growth factor (OGF) inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. Int J Oncol 2004;24:227-32.
62. McLaughlin PJ, Stack BC Jr, Levin RJ, Fedok F, Zagon IS. Defects in the OGF receptor (OGFr) in human squamous cell carcinoma of the head and neck. Cancer 2003;97:1701-10.
63. Donahue RN, Zagon IS, McLaughlin PJ. The opioid growth factor inhibits established ovarian cancer in nude mice and can be combined with taxol or cisplatin to enhance growth inhibition. J Cancer Ther 2011;2:110-24.
64. Donahue RN, McLaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol 2011;122:382-8.
65. Donahue RN, McLaughlin PJ, Zagon IS. Overexpression of the opioid growth factor receptor (OGFr) in human ovarian cancer cells downregulates cell proliferation in vitro and inhibits tumorigenesis in mice. J Cancer Ther 2011;2:579-94.
66. Donahue RN, McLaughlin PJ, Zagon IS. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer. Exp Biol Med 2012;237:167-77.
67. Fanning J, Hossler CA, Kesterson JP, Donahue RN, McLaughlin PJ, Zagon IS. Expression of the opioid growth factor -opioid growth factor receptor axis in human ovarian cancer. Gynecol Oncol 2012;124:319-24.
68. Zagon IS, McLaughlin PJ. 1995. Gene-peptide relationships in the developing rat brain: The response of preproenkephalin mRNA and [Met5]-enkephalin to acute opioid antagonist (naltrexone) exposure. Mol Brain Res 1995;33:111-20.
69. Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med 2011;236:1036-50.
70. Donahue RN, McLaughlin PJ, Zagon IS. Low dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med 2011;236:883-95.
71. McLaughlin PJ, Jaglowski JR, Verderame MF, Stack BC, LeureduPree AE, Zagon IS. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. Int J Oncol 2005;26:809-16.
72. Jaglowski JR, Zagon IS, Stack BC, Verderame MF, Leure-duPree AE, Manning JD, McLaughlin PJ. Opioid growth factor enhances tumour growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol 2005;56:97-104.
73. Zagon IS, Jaglowski JR, Verderame MF, Leure-duPree AE, Smith JP, McLaughlin PJ. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2005;56:510-20.
74. McLaughlin PJ, Stucki JK, Zagon IS. Modulation of the opioid growth factor ([Met5]-enkephalin) -opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck. Head Neck 2012;34:513-19.
75. Hytrek SD, McLaughlin PJ, Lang CM, Zagon IS. Inhibition of human colon cancer by intermittent opioid receptor blockade with naltrexone. Cancer Lett 1996;101:159-64.
76. McLaughlin PJ, Zagon IS. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor (OGFr). Int J Oncol 2006;28:1577-83.
77. McLaughlin PJ, Verderame MF, Hankins JL, Zagon IS. Overexpression of the opioid growth factor receptor downregulates cell proliferation of human squamous carcinoma cells of the head and neck. Int J Mol Med 2007;19:421-8.
78. Zagon IS, Verderame MF, Hankins JL, McLaughlin PJ. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol 2007;30:775-83.
79. McLaughlin PJ, Kreiner S, Morgan CR, Zagon IS. Prevention and delay in progression of human squamous cell carcinoma of the head and neck in nude mice by stable overexpression of the opioid growth factor receptor. Int J Oncol 2008;33:751-7.
80. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell 2009;20:319-27.
81. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res 2007;67:10511-18.
82. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer 2008;7:5-17.
83. Smith JP, Conter RL, Bingaman SI, Harvey JA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin, Zagon IS. Treatment of advanced pancreatic cancer with opioid growth factor: Phase I. Anti Cancer Drug 2004;15:203-9.
84. Smith JP, Bingaman SI, Mauger DT, Harvey HA, Demers LM, Zagon IS. Opioid growth factor (OGF) improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access J Clinical Trials 2010;2:37-48